TheEdgeResearch
Home / Stocks / CUE

Cue Biopharma, Inc. (CUE)

NASDAQ Healthcare Biotechnology
$36.51 ▲ +3.28%
Market Cap
$95.9M
Sector
Healthcare
Industry
Biotechnology
Beta
2.46
52-Wk Range
4.98-41.42
CEO
Lucinda Warren
Country
US
Currency
USD

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific T cells involved in cancers originating from huma…

Open full interactive analysis & DCF →